Literature DB >> 34318397

Diagnostic challenges in primary cardiac lymphoma, the opportunity of 18F-FDG PET/CT integrated with contrast-enhanced CT.

Entao Liu1,2, Jia Huang3, Haojian Dong4, Zerui Chen5, Chao Liu6, Qiu Xie7, Weiping Xu2, Shuxia Wang2, Zaiyi Liu8,9.   

Abstract

BACKGROUND: The purpose of this study was to retrospectively evaluate the value of 18F-FDG PET/CT integrated with contrast-enhanced CT (CECT) in the differential diagnosis of primary cardiac lymphomas (PCLs) and primary cardiac angiosarcomas (PCAs).
METHODS: Clinical and imaging data of patients with PCLs and PCAs were collected. All patients underwent preoperative 18F-FDG PET/CT and thoracic CECT. The enhancement pattern and tumor morphology were analyzed using CECT images. The intensity- and volume-based PET parameters of cardiac lesions were analyzed. The performance characteristics of all parameters were assessed.
RESULTS: Nine patients with PCL and eight patients with PCA were analyzed. There were significant differences in SUVmax (t = 3.790, P = .002), SUVmean (t = 4.273, P = .001), metabolic tumor volume (U = 13.00, P = .027), tumor-to-liver ratio (U = 10.00, P = .011), and total lesion glycolysis (U = 4.0, P = .001) between PCLs and PC18As. There were significant differences in the enhancement pattern of tumors (P = .002) and tumor morphology (P = .015). The combination of F-FDG PET/CT and CECT improved the diagnostic accuracy, and the combination cutoff (SUVmean > 5.17) could reach 100%, but the difference was not statistically significant (P > .05).
CONCLUSION: The intensity- and volume-based PET parameters of PCL were significantly higher than those of PCA. The enhancement pattern and tumor morphology were also different. According to these characteristics, the two most common types of primary cardiac malignancies can be differentiated.
© 2021. American Society of Nuclear Cardiology.

Entities:  

Keywords:  Angiosarcoma; Cardiac tumors; Lymphoma; PET/CT; Tomography; X-ray computed

Mesh:

Substances:

Year:  2021        PMID: 34318397     DOI: 10.1007/s12350-021-02723-6

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   3.872


  6 in total

1.  Coronary vessel floating sign in cardiac diffuse large B-cell lymphoma.

Authors:  Shu Yoshihara; Yuya Sugimoto; Masaki Matsunaga; Shioto Suzuki; Fumihiko Tanioka
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2020-02-01       Impact factor: 6.875

2.  Coronary vessel floating sign and vasospastic angina in a patient with cardiac lymphoma.

Authors:  Akio Chikata; Satoru Sakagami; Naomi Kanamori; Chieko Kato; Wataru Omi; Takahiro Saeki; Hideo Nagai; Atsuhiro Kawashima; Soichiro Usui; Masayuki Takamura
Journal:  Int J Cardiol       Date:  2014-07-08       Impact factor: 4.164

3.  Assessment of cardiac tumors by 18F-FDG PET/CT imaging: Histological correlation and clinical outcomes.

Authors:  Jingjing Meng; Xiang Li; Honglei Zhao; Yongmin Liu; Dong Chen; Marcus Hacker; Yongxiang Wei; Xiaoli Zhang; Michael C Kreissl
Journal:  J Nucl Cardiol       Date:  2020-01-13       Impact factor: 5.952

4.  Diagnosis and treatment complications of primary cardiac lymphoma in an immunocompetent 28-year old man: a case report.

Authors:  Maria Bonou; Chris J Kapelios; Athanasios Marinakos; Stamatis Adamopoulos; Panagiotis Diamantopoulos; Periklis G Foukas; Loukas Kaklamanis; Penelope Korkolopoulou; John Barbetseas; Nora-Athina Viniou
Journal:  BMC Cancer       Date:  2019-03-01       Impact factor: 4.430

5.  Combined PET/CT with thoracic contrast-enhanced CT in assessment of primary cardiac tumors in adult patients.

Authors:  En-Tao Liu; Tao-Tao Sun; Hao-Jian Dong; Si-Yun Wang; Ze-Rui Chen; Chao Liu; Dan Shao; Zhou-Yang Lian; Qiu Xie; Shu-Xia Wang
Journal:  EJNMMI Res       Date:  2020-07-06       Impact factor: 3.138

6.  For avid glucose tumors, the SUV peak is the most reliable parameter for [(18)F]FDG-PET/CT quantification, regardless of acquisition time.

Authors:  Avigaëlle Sher; Franck Lacoeuille; Pacôme Fosse; Laurent Vervueren; Aurélie Cahouet-Vannier; Djamel Dabli; Francis Bouchet; Olivier Couturier
Journal:  EJNMMI Res       Date:  2016-03-05       Impact factor: 3.138

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.